In preclinical mouse models of SCLC, VEGFA could enhance the expression of the alternate inhibitory receptor TIM-3 in T cells from mice treated with anti-PD-L1 alone, leading to an exhausted T cell phenotype that was reversed with the addition of anti-VEGF[108]. The gene discussed is VEGFA; the disease is small cell lung carcinoma.